16 March 2015
ASLAN announces positive phase 1 results
with ASLAN002
29 January 2015
ASLAN appoints Dr Bertil Lindmark as CSO
10 January 2015
ASLAN presents at East/West Biotech CEO conference in San Francisco

Our Model
ASLAN inlicenses preclinical candidate drugs and takes them to proof-of-concept, leveraging high quality resources in Asia, then offers them back to the originator or other pharma companies for late phase global development.
ASLAN is currently looking to inlicense preclinical and early development compounds into our pipeline across a variety of therapeutic areas

Home | Our Model Our Team Our Board | Pipeline | Asset Partners | Latest News | Careers
    Our Advisors Our Investors         Execution Partners   Archive   Location

Copyright ©2010 ASLAN Pharmaceuticals Pte Ltd